Coeptis Therapeutics Holdings Inc. - COEP STOCK NEWS

Coeptis Therapeutics (NASDAQ: COEP) announced a proposed transaction to acquire assets from Deverra Therapeutics, focusing on NK cell therapies for relapsed/refractory acute myeloid leukemia (AML) and respiratory infections. The agreement grants Coeptis exclusive negotiation rights until August 31, 2023, for two IND applications and Phase 1 trials involving NK cell therapy. This acquisition aims to enhance Coeptis' R&D capabilities and diversify its portfolio by integrating a proven allogeneic platform that requires no HLA matching. With anticipated Phase 1 AML trial data expected in 2H 2023, the deal could significantly expand Coeptis' technological footprint. If completed, Deverra's CSO, Dr. Colleen Delaney, is expected to join Coeptis as Chief Scientific and Medical Officer.

Coeptis Therapeutics Holdings (NASDAQ: COEP) has acquired exclusive rights to negotiate for the acquisition of VyGen-Bio, enhancing its oncology pipeline. The GEAR™ Platform and companion diagnostic technologies from VyGen-Bio will support the development of advanced cell therapies targeting CD38+ cancers, including multiple myeloma. Coeptis will initiate due diligence on VyGen-Bio’s assets, focusing on GEAR-NK cell therapy. The companies aim to leverage their collaboration to improve patient outcomes and expand treatment options in immuno-oncology. Successful completion of this transaction could mark a significant growth milestone for Coeptis.

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) announced that its SNAP-CAR technology was featured in a peer-reviewed article in the Journal of Translational Medicine on March 21, 2023. The SNAP-CAR platform, designed for multi-antigen targeting, aims to enhance the efficacy and safety of CAR T therapies for various cancers. The article highlights its potential to overcome limitations of current CAR T technologies by linking antibodies to universal CAR receptors. Coeptis plans to target HER2-expressing ovarian cancer as part of its first-in-human clinical development program, with the technology licensed from the University of Pittsburgh.

Coeptis Therapeutics (NASDAQ: COEP) has engaged Shareholder Intelligence Services (ShareIntel) for a comprehensive 12-month agreement to monitor and analyze trading patterns of its common stock. This partnership aims to identify illegal short selling and enhance shareholder protections. ShareIntel's DRIL-Down™ technology will track trading anomalies and provide valuable insights into market activities. Coeptis is committed to safeguarding shareholder interests and preventing market manipulation, according to CEO Dave Mehalick. The collaboration is part of Coeptis's broader strategy to protect its stock's value while advancing its cancer treatment platforms.